Please assess the completion status of the following clinical trial:

Trial Title: Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Patients with symptomatic large vessel occlusion (LVO) in the anterior, middle or posterior cerebral artery treated with MT resulting in an mTICI score 2b/3 at end of the procedure.. Patients with an mTICI score 2b/3 on the diagnostic cerebral angiography before the onset of MT are also eligible for the study.~2. Estimated delay to onset of rescue intraarterial rt-PA administration \<24 hours from symptom onset, defined as the point in time the patient was last seen well~3. No significant pre-stroke functional disability (modified Rankin scale 0-1), or mRS \>1 that according to the investigator is not related to neurological disease (i.e. amputation, blindness)~4. Age ≥18~5. ASPECTS \>6 on non-contrast CT (NCCT) scan or MRI if symptoms lasting \<4.5 hours or ASPECTS \>6 on CT-Perfusion (CTP) or DWI-MRI if symptoms \>4.5 \<24 hours.~6. Informed consent obtained from patient or acceptable patient surrogate~EXCLUSION CRITERIA:~1. NIHSS score on admission \>25~2. Contraindication to IV t-PA as per local national guidelines (except time to therapy)~3. Use of carotid artery stents during the endovascular procedure requiring dual antiplatelet therapy during the first 24h~4. Female who is pregnant or lactating or has a positive pregnancy test at time of admission~5. Current participation in another investigation drug or device treatment study (except observational study i.e.: RACECAT or clinical trials not testing new medical devices or new drugs i.e.IMAGECAT)~6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency~7. Known coagulopathy, INR \> 1.7 or use of novel anticoagulants \< 48h from symptom onset~8. Platelets \< 50,000~9. Renal Failure as defined by a serum creatinine \> 3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate \[GFR\] \< 30~10. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason~11. Any hemorrhage on CT/MRI~12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal~13. Suspicion of aortic dissection~14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol~15. History of life threatening allergy (more than rash) to contrast medium~16. SBP \>185 mmHg or DBP \>110 mmHg refractory to treatment~17. Serious, advanced, terminal illness with anticipated life expectancy \< 6 months~18. Pre-existing neurological or psychiatric disease that would confound evaluation~19. Presumed vasculitis or septic embolization~20. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraarterial alteplase (Type: EXPERIMENTAL): All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~1. Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)
- Placebo (Type: PLACEBO_COMPARATOR): The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~1. Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)

Based on this trial design, predict the completion outcome and termination type (if applicable).